Evidence mapping of treatment landscape in Chinese patients with metastatic prostate cancer

Wanqing Li, Dingkun Hou, Zhenhua Liu, Luyao Yang, Liang Ding, Haitao Wang2024 · DOI

This document outlines a research protocol for an upcoming systematic review and evidence mapping study. It is not a report of final results, but rather a blueprint for how researchers intend to investigate the treatment of metastatic prostate cancer (mPC) in China.

TL;DR

Researchers are launching a comprehensive evidence-mapping project to bridge the gap between international clinical guidelines and the "real-world" treatment of metastatic prostate cancer in China. By systematically reviewing both Chinese and international literature, the team aims to identify where clinical practice falls short of recommendations and where local research needs to catch up.

What Problem Does This Paper Address?

Prostate cancer (PC) is a growing health crisis in China, with incidence rates rising annually. Critically, about 68% of patients are already at an advanced stage upon their first diagnosis. While the Chinese Society of Clinical Oncology (CSCO) provides treatment guidelines, these recommendations are largely based on clinical trials conducted in Western populations.

The authors identify a significant "knowledge-to-action" gap:

  1. Clinical Reality vs. Guidelines: It is unclear how closely actual treatments in Chinese hospitals align with the latest expert consensus.
  2. Data Scarcity: There is a lack of recent data regarding the incidence of mPC in China and the prevalence of genetic testing (like NGS or PCR) used to guide precision medicine.
  3. Research Gaps: There is a need to understand how Chinese patients respond to newer therapies, such as PARP inhibitors (e.g., olaparib), compared to global benchmarks.

Methods

The study will follow a rigorous systematic review and evidence-mapping framework. Key components include:

  • Evidence Mapping: Unlike a standard meta-analysis that seeks a single numerical answer, evidence mapping provides a high-level overview of the "landscape"—identifying what has been studied, where the research is geographically concentrated, and what interventions are most common.
  • Dual-Language Search: The team will query both international databases (PubMed, Cochrane, Embase) and major Chinese-specific databases (CNKI, Wanfang, VIP) to ensure local clinical data is not overlooked.
  • Two-Phase Screening: Two independent reviewers will screen titles and abstracts, followed by a full-text review. Discrepancies will be resolved by a third reviewer to ensure objectivity.
  • Thematic Synthesis: Data will be categorized by the two primary types of metastatic cancer: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and Metastatic Castration-Resistant Prostate Cancer (mCRPC).
  • Tools: The researchers will utilize Rayyan for collaborative screening, Endnote for citation management, and Chiplot Tools for the final visual evidence mapping.

Datasets

As this is a protocol for a systematic review, the "datasets" are the literature repositories being searched:

  • International: PubMed, Cochrane Library, Embase, CENTRAL.
  • Chinese: China National Knowledge Infrastructure (CNKI), Wanfang Database, and VIP Database for Chinese Technical Periodicals.
  • Registries: The Chinese Clinical Trials Registry Center will be searched for ongoing or unpublished protocols.

Key Insights and Ideas

  • The "Guideline Paradox": The authors highlight that while Chinese guidelines are consistent with international standards (NCCN, EAU, JUA), the evidence supporting them is often "imported." This study seeks to find "Chinese evidence for Chinese patients."
  • Focus on Precision Medicine: A major focus of the map will be the status of genetic testing. As therapies like PARP inhibitors become more common, understanding the "testing landscape" (germline vs. somatic mutations) is essential for determining if patients are actually receiving the targeted therapies they need.
  • Identifying "Research Deserts": By mapping the distribution of studies, the authors hope to show which regions or patient subgroups in China are currently underserved by clinical research.

Key Results

Not discussed in the paper. As this is a registered protocol (INPLASY202460064), the results are currently in the data collection and "piloting" phase. The protocol was registered and last updated on June 17, 2024.

Limitations and Future Work

  • Publication Bias: The study relies solely on published literature. If certain clinical outcomes or "failed" treatments are not published in journals, they will not be captured in this evidence map.
  • Data Quality: The map is only as good as the underlying studies. The researchers note that they will need to assess the quality and relevance of data, particularly from secondary sources like electronic health records.
  • Future Work: Once the map is complete, the authors intend for it to serve as a foundational reference for policymakers and clinicians to improve treatment outcomes and promote more targeted research within the Chinese healthcare system.

Summary updated

Abstract

Review Stage at time of this submission -Piloting of the study selection process
BibTeX
@misc{li2024evidence,
  author = {Wanqing Li and Dingkun Hou and Zhenhua Liu and Luyao Yang and Liang Ding and Haitao Wang},
  title = {{Evidence mapping of treatment landscape in Chinese patients with metastatic prostate cancer}},
  year = {2024},
  doi = {10.37766/inplasy2024.6.0064},
}
Figure